CareDx (CDNA) Upgraded to C- by TheStreet

CareDx (NASDAQ:CDNA) was upgraded by analysts at TheStreet from a “d-” rating to a “c-” rating in a research report issued to clients and investors on Tuesday.

Several other research analysts have also commented on CDNA. HC Wainwright set a $12.00 price target on CareDx and gave the stock a “buy” rating in a research report on Monday, April 2nd. ValuEngine raised CareDx from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research raised CareDx from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research report on Wednesday, January 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. CareDx currently has an average rating of “Buy” and a consensus target price of $8.65.

CDNA opened at $8.62 on Tuesday. The company has a market cap of $252.66, a price-to-earnings ratio of -11.19 and a beta of 0.37. CareDx has a 52 week low of $0.76 and a 52 week high of $8.99. The company has a current ratio of 0.62, a quick ratio of 0.50 and a debt-to-equity ratio of -3.08.



CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Thursday, March 22nd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. The company had revenue of $12.50 million for the quarter, compared to analyst estimates of $12.09 million. CareDx had a negative return on equity of 349.65% and a negative net margin of 114.79%. equities analysts predict that CareDx will post -0.34 earnings per share for the current fiscal year.

In other news, insider Peter Maag sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 27th. The stock was sold at an average price of $7.87, for a total value of $118,050.00. Following the transaction, the insider now owns 272,037 shares of the company’s stock, valued at $2,140,931.19. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 5.40% of the company’s stock.

Several large investors have recently added to or reduced their stakes in CDNA. Royce & Associates LP increased its holdings in shares of CareDx by 8.1% in the third quarter. Royce & Associates LP now owns 792,787 shares of the company’s stock valued at $2,933,000 after purchasing an additional 59,500 shares during the period. Bank of Montreal Can acquired a new position in shares of CareDx in the fourth quarter valued at approximately $130,000. FNY Partners Fund LP acquired a new position in shares of CareDx in the fourth quarter valued at approximately $102,000. Perkins Capital Management Inc. increased its holdings in shares of CareDx by 28.9% in the fourth quarter. Perkins Capital Management Inc. now owns 178,639 shares of the company’s stock valued at $1,311,000 after purchasing an additional 40,089 shares during the period. Finally, Private Wealth Partners LLC increased its holdings in shares of CareDx by 85.5% in the fourth quarter. Private Wealth Partners LLC now owns 436,000 shares of the company’s stock valued at $3,200,000 after purchasing an additional 201,000 shares during the period. 51.50% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “CareDx (CDNA) Upgraded to C- by TheStreet” was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://dakotafinancialnews.com/2018/04/12/caredx-cdna-upgraded-to-c-by-thestreet.html.

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply